Leo V. Lacerna

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

Adam Brufsky, W G Harker, J. Thaddeus Beck et al. · Journal of Clinical Oncology · 2006 · 321 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer

Christopher W. Ryan, Dezheng Huo, Laurence M. Demers et al. · The Journal of Urology · 2006 · 126 citations

Medicine, Endocrinology, Oncology +17

The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy

Ron Israeli, Steven Rosenberg, Daniel R. Saltzstein et al. · Clinical Genitourinary Cancer · 2007 · 108 citations

Medicine, Endocrinology, Bone Metabolism +15

Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy

Charles L. Vogel, Ronald Yanagihara, Albert J. Wood et al. · The Oncologist · 2004 · 76 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial

Adam Brufsky, W G Harker, J. Thaddeus Beck et al. · Journal of Clinical Oncology · 2005 · 54 citations

Medicine, Pharmacology, Pharmacotherapy +17